Blood bank genetics review

Immunology in transfusion medicine: key concepts

  • Maternal antibodies and tolerance

    • Maternal-derived immune components can persist for about 30 to 90 days30\text{ to }90\ \text{days} after birth, but then become undetectable as they clear from the infant. This reduction helps establish tolerance and lowers the risk of alloimmunization.
    • If a true antibody forms against recipient antigens, that antibody persists and remains a risk for the rest of the patient’s life.
    • The goal is to prevent the antibody from forming in the first place; once formed, antibodies are not easily eliminated.

  • Complement activation in transfusion and immunology

    • Complement cascade is a key concept you’ll encounter in hematology and immunology.
    • In transfusion medicine, we generally want to avoid activating the complement cascade to prevent hemolysis of transfused red blood cells.
    • Antibody isotypes and their ability to activate complement:
    • IgM is large and multivalent; a single IgM molecule can activate complement and trigger the cascade.
      • This is due to the pentameric structure, which presents multiple binding sites.
    • IgG requires at least two molecules (dimers/aggregates) to effectively activate complement.
    • Resulting hemolysis can be intravascular or extravascular depending on where the cascade completes.

  • Hemolysis: intravascular vs extravascular

    • Intravascular hemolysis
    • Occurs within blood vessels; the complement cascade completes and red cells lyse in circulation.
    • Can be life-threatening: may cause anaphylaxis and renal failure; if untreated, can be fatal.
    • Often associated with severe and rapid hemolysis, such as in ABO-incompatible transfusions.
    • Extravascular hemolysis
    • Slower process; red cells are coated with complement component C3 and are removed by phagocytes (mostly in the spleen/liver).
    • The cascade usually halts at the C3 stage and does not proceed to full lysis.
    • Not typically life-threatening, but results in decreased red cell survival and anemia; causes reduced lifespan of transfused RBCs (instead of ~120 days120\text{ days}, survival is shorter).

  • ABO compatibility and transfusion safety

    • In ABO incompatibility, intravascular hemolysis can start very quickly, potentially within 1$-$2\ \text{mL} of incompatible blood transfused.
    • This is why stopping a transfusion and preventing exposure to incompatible blood is critical.

  • Genetic basis of antigens and blood groups

    • Antigens arise from genetics; humans have 4646 chromosomes.
    • The specific location of a gene on a chromosome is called a locus.
    • Different forms of a gene are alleles.
    • A silent or non-expressed gene is called an amorph (amorph) allele.
    • Key genetic terms:
    • Dominant: an allele that can determine the phenotype even if only one copy is present.
    • Recessive: an allele that is expressed only when two copies are present.
    • Homozygous: two identical alleles at the same locus.
    • Heterozygous: two different alleles at the same locus.
    • Codominant: both alleles are expressed in the phenotype when present (e.g., AB blood type).

  • Illustrative example: blood type genetics and dominance

    • Dominant vs recessive basics (hair color analogy): brown (dominant) vs red (recessive) hair; brown will be expressed if either brown or red allele is present; red expresses only if both recessive alleles are present.
    • Codominance example: AB blood type expresses both A and B antigens when both alleles are present.

  • ABO blood types and genotypes

    • Genotype possibilities at the ABO locus:
    • Group A: AA or AO (AO is often described as heterozygous; AO contains one active A allele and one O allele)
    • Group B: BB or BO
    • Group AB: AB (codominant expression of both A and B antigens)
    • Group O: OO (no A or B antigens expressed)
    • Phenotype vs genotype:
    • Phenotype is the observable blood group (what you test in the lab).
    • Genotype is the underlying combination of alleles (AA, AO, BB, BO, AB, OO).
    • Important lab caveats:
    • For phenotype determinations, we usually do not know genotype (homozygous vs heterozygous) from standard blood bank tests alone.
    • A person with phenotype A could be AA (homozygous) or AO (heterozygous). A person with phenotype B could be BB or BO. AB phenotype corresponds to AB genotype (no alternative), and O phenotype corresponds to OO genotype.
    • Do not assume genotype based solely on phenotype; additional testing would be required to determine zygosity.

  • Punnett squares and genotype/phenotype mapping (conceptual examples)

    • Example cross: AA × AO
    • Possible offspring genotypes: AA and AO (in this cross, you’ll get two AA and two AO in a 1:1 ratio in a simplified 2x2 Punnett setup).
    • In terms of zygosity:
      • AA: homozygous
      • AO: heterozygous
    • Example cross: AO × AO
    • Possible offspring genotypes: AA, AO, and OO (1:2:1 ratio in a standard Punnett square).
    • Phenotypes reflect the expressed blood groups: AA and AO express type A; OO expresses type O.
    • Practical interpretation in labs
    • Phenotype-based testing: determine the expressed blood group (A, B, AB, O).
    • Genotype determination (homozygous vs heterozygous) typically requires additional genetic testing beyond standard serology.
    • Scenario illustration for expression
    • If the child has phenotype A, it could be AA or AO genotype; either way, the observed phenotype is A in standard tests.
    • If the child has phenotype O, genotype must be OO.
    • If the child has phenotype AB, genotype is AB (codominant expression of A and B).

  • Age-related considerations in infancy and antibody development

    • Antibody development in infants (back typing and testing):
    • Antibodies against ABO or other antigens may not be detectable immediately in infancy; they commonly become detectable around several months of age.
    • The transcript notes a practical point: antibodies may be weakly expressed early on, and many labs do not perform backward typing (back typing) until after several months of age because antibodies become more specific and detectable over time.
    • Practical implication: transfusion and crossmatching strategies in newborns may rely more on forward typing and phenotypic compatibility, with serologic refinements pursued as the child ages.

  • Practical and ethical implications for transfusion practice

    • Preventing alloimmunization and antibody formation reduces future transfusion risks and complications.
    • Avoiding complement activation during transfusion improves patient safety by reducing hemolytic risk.
    • Timely recognition of intravascular hemolysis is critical and can be life-saving; stopping an incompatible transfusion is essential.
    • Proper interpretation of genetic information informs understanding of potential donor–recipient antigen compatibility and future compatibility considerations in patients.

  • Connections to foundational concepts and real-world relevance

    • Connects to basic immunology: antibody structure (IgM vs IgG), complement activation, and how immune responses can target transfused cells.
    • Relevance to clinical practice: safe transfusion strategies depend on understanding intravascular vs extravascular hemolysis, antibody formation, and genetic determinants of blood groups.
    • Ethical/practical dimension: patient safety requires strict matching and vigilance to minimize immunologic risk and transfusion reactions.

  • Notable numerical references and formulas

    • Chromosomes: 4646 per human
    • Red cell lifespan: typically 120 days120\text{ days}, can be shortened by hemolysis
    • Antibody development window in infancy: about 4 months4\text{ months} before antibodies are reliably detectable in some cases
    • Incompatible transfusion risk threshold: intravascular hemolysis can begin with as little as 1 to 2 mL1\text{ to }2\ \text{mL} of incompatible blood

  • Summary of key distinctions and take-home messages

    • IgM can activate complement with a single molecule; IgG generally needs two molecules for activation.
    • Intravascular hemolysis is acute and potentially fatal; extravascular hemolysis is slower but reduces RBC survival.
    • ABO incompatibility triggers rapid intravascular hemolysis if not halted.
    • The genotype–phenotype distinction is central in interpreting blood groups; phenotype reflects what is observed, while genotype reveals underlying alleles, which may be homozygous or heterozygous.
    • Codominance (as in AB blood type) results in expression of both alleles in the phenotype.
    • In infants, antibody development can be delayed, influencing when and how testing is performed in the lab.

  • Quick reference labs and terminology

    • Locus: position of a gene on a chromosome
    • Alleles: different forms of a gene
    • Amor ph: silent or non-expressed allele
    • Dominant vs recessive: expression depends on allele presence
    • Homozygous vs heterozygous: same or different alleles at a locus
    • Codominant: both alleles contribute to the phenotype
    • Phenotype vs genotype: observable traits vs genetic makeup

  • How this ties into laboratory detection

    • In the lab, most routine blood typing determines phenotype; genotype determination requires specialized genetic testing.
    • When interpreting questions or problems, avoid assuming homozygosity based solely on phenotype; confirm if genotype data is provided or required.